NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Enlivex Therapeutics Ltd (TA: ENLV)

 
ENLV Technical Analysis
5
As on 30th Jul 2025 ENLV STOCK Price closed @ 485.00 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 660.90 & Strong Sell for SHORT-TERM with Stoploss of 1197.21 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ENLVSTOCK Price

Open 456.90 Change Price %
High 510.00 1 Day 35.60 7.92
Low 456.90 1 Week 70.60 17.04
Close 485.00 1 Month 137.80 39.69
Volume 159774 1 Year -492.20 -50.37
52 Week High 1581.00 | 52 Week Low 318.50
 
TA Israel Most Active Stocks
TA125 2008.05 1.06%
ISCD 1418.00 2.01%
ORL 89.60 -2.50%
TEVA 5690.00 2.34%
CANF 1.00 0.00%
BEZQ 638.70 -0.08%
BLRX 2.50 0.00%
GODM 55.00 3.58%
PPBT 3.80 -5.00%
GNRS 106.50 -2.11%
 
TA Israel Top Gainers Stocks
SVRT 307.00 24.64%
TDGN-L 171.50 17.55%
MCRNT 372.50 16.84%
INBR 500.00 14.16%
ITYF 500.00 14.16%
HDST 45.00 13.07%
HDST 45.00 13.07%
CNMD 45.10 10.54%
CNMD 45.10 10.54%
GIX 4850.00 9.48%
 
TA Israel Top Losers Stocks
KMNK 51.00 -23.19%
PLAZ 104.00 -21.15%
PLAZ 104.00 -21.15%
ULTR 74.10 -16.74%
INSL 265.30 -11.57%
EFNC 265.30 -11.57%
FVT 390.00 -11.36%
FVT 390.00 -11.36%
FVT 390.00 -11.36%
BSP 250.00 -9.65%
 
 
ENLV
Daily Charts
ENLV
Intraday Charts
Whats New @
Bazaartrend
ENLV
Free Analysis
 
ENLV Important Levels Intraday
RESISTANCE587.32
RESISTANCE554.51
RESISTANCE534.22
RESISTANCE513.94
SUPPORT456.06
SUPPORT435.78
SUPPORT415.49
SUPPORT382.68
 
ENLV Forecast July 2025
4th UP Forecast2643.24
3rd UP Forecast1951.08
2nd UP Forecast1523.24
1st UP Forecast1095.4
1st DOWN Forecast-125.4
2nd DOWN Forecast-553.24
3rd DOWN Forecast-981.08
4th DOWN Forecast-1673.24
 
ENLV Weekly Forecast
4th UP Forecast1082.37
3rd UP Forecast890.79
2nd UP Forecast772.37
1st UP Forecast653.95
1st DOWN Forecast316.05
2nd DOWN Forecast197.63
3rd DOWN Forecast79.21
4th DOWN Forecast-112.37
 
ENLV Forecast2025
4th UP Forecast2972.18
3rd UP Forecast2174.53
2nd UP Forecast1681.48
1st UP Forecast1188.43
1st DOWN Forecast-218.43
2nd DOWN Forecast-711.48
3rd DOWN Forecast-1204.53
4th DOWN Forecast-2002.18
 
 
ENLV Other Details
Segment EQ
Market Capital 50720083968.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
ENLV Address
ENLV
 
ENLV Latest News
 
Your Comments and Response on Enlivex Therapeutics Ltd
 
ENLV Business Profile
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel. Address: 14 Einstein Street, Ness Ziona, Israel, 7403618
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service